Trump expands access to cannabis in a major shift in drug policy

In a major shift in US drug policy, former President Donald Trump has expanded access to cannabis by reclassifying it to the same category as Tylenol with codeine. This move marks the most significant change in US drug policy since 1971. The new classification places cannabis in a more permissive category, making it easier for researchers to study the drug and potentially leading to the development of new medical treatments. It also reduces the legal penalties associated with cannabis possession and usage. The decision has been praised by advocates of cannabis legalization, who view it as a step towards the normalization of the drug. However, it has also faced criticism from some who argue that it does not go far enough in addressing the broader issue of drug policy reform. Overall, the reclassification of cannabis represents a notable shift in the federal government's approach to the drug, with potentially far-reaching implications for the future of US drug policy.